Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial.
about
Human cytomegalovirus and transplantation: drug development and regulatory issuesCMV in Hematopoietic Stem Cell TransplantationCMV: Prevention, Diagnosis and TherapyCytomegalovirus antivirals and development of improved animal modelsHow I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipientsPeptide vaccination in the presence of adjuvants in patients after hematopoietic stem cell transplantation with CD4+ T cell reconstitution elicits consistent CD8+ T cell responses.Management of cytomegalovirus infection and disease in liver transplant recipients.Inactivation of enveloped virus by laser-driven protein aggregation.Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient.Progress in the development of new therapies for herpesvirus infectionsThe biology of cytomegalovirus drug resistanceValganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trialCMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRβ repertoireClinical Development of a Cytomegalovirus DNA Vaccine: From Product Concept to Pivotal Phase 3 TrialCytomegalovirus: recent progress in understanding pathogenesis and controlHerpes simplex viruses: mechanisms of DNA replication.Priorities for CMV vaccine developmentEfficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation.The ULb' region of the human cytomegalovirus genome confers an increased requirement for the viral protein kinase UL97.Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis.Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study.Hsp90 inhibitor 17-DMAG decreases expression of conserved herpesvirus protein kinases and reduces virus production in Epstein-Barr virus-infected cellsWhy CMV is a candidate for elimination and then eradication.Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016.Cytomegalovirus pneumonia in hematopoietic stem cell recipients.Human Cytomegalovirus Can Procure Deoxyribonucleotides for Viral DNA Replication in the Absence of Retinoblastoma Protein Phosphorylation.Differential properties of cytomegalovirus pUL97 kinase isoforms affect viral replication and maribavir susceptibilityPhosphorylation events during viral infections provide potential therapeutic targets.Human cytomegalovirus infection and atherothrombosis.Management of multidrug-resistant viruses in the immunocompromised host.Molecular diagnosis and management of viral infections in hematopoietic stem cell transplant recipients.Cytomegalovirus infection and the gastrointestinal tract.Therapeutic strategies for the prevention and treatment of cytomegalovirus infection.Recent progress in managing graft-versus-host disease and viral infections following allogeneic stem cell transplantation.Delayed opportunistic infections in hematopoietic stem cell transplantation patients: a surmountable challengeClinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients.Potential of protein kinase inhibitors for treating herpesvirus-associated disease.Therapeutic strategies for cytomegalovirus infection in haematopoietic transplant recipients: a focused update.Design and development of antivirals and intervention strategies against human herpesviruses using high-throughput approach.The pathogenesis of human cytomegalovirus.
P2860
Q26700020-7FFBF1D2-055C-4A43-BF5E-65B92115E2DDQ26740385-30FD6F2B-7F60-4EDD-AD3F-55FA23EDEAF2Q26824869-6F7F9B93-2600-42C2-B70F-ACFC7992B538Q27000998-B57C8C4A-B763-4D7C-9806-7D87E3270CC9Q28069489-6F1A7F28-7F65-4E6E-AB4E-357F5183CC9BQ33703139-0F9B5DFF-2528-44B0-A689-B6E336C4D83EQ33845124-A434674D-19CA-478D-9294-38CDB296E444Q34504426-707B2B1A-E929-4323-83A8-BF34722AE97AQ34841085-13EE47EA-E309-49DF-9D14-F7DA6F7FD4A7Q35590695-04FDAF0C-7476-47D7-9F92-28E3644116F8Q35684511-D0A8C05A-BD2B-4655-9531-DE6F59824852Q35735525-4AB6EF6F-2561-4430-9DF5-38832AFBFB95Q35757381-4EC0DA44-5AAF-4F30-A48C-9AC38326E3C9Q35826628-67498602-EA56-4063-9340-0B93DD2774E0Q35895910-3B46AF22-CFD3-466D-943D-2AC0227E8487Q36192926-A716B40F-931D-4281-80C1-F64EC7B04407Q36216553-78FBA840-2177-47EF-96AB-6A6EF99FD02CQ36306393-5FA1057C-F241-45AA-A10C-D4C15CA44872Q36827232-80725189-E3EE-4BB7-8091-FB61F32FF15EQ36920445-399D470F-6F80-44CF-9BE5-B326BA82F84BQ37022512-3BE50602-18F7-4792-A592-E85D1391A605Q37123188-E77FDB16-B933-48B0-8479-6365E8DB3037Q37141395-1B8F935A-7400-4C09-97B7-DD31F3623EBEQ37150434-59083E48-3887-4309-9A9A-A6BEE3692F74Q37179131-53D005A9-DC30-42DC-B328-894066F5319DQ37252945-D247CAC4-0FC5-4212-A282-B2FD3A862CD1Q37713957-9ECDB369-2D35-4997-ADCA-8807771FBB0CQ37960427-FD3A14B3-D46B-4AA4-9F12-D36B4EF990E5Q37967568-5215B4A3-B62B-4C72-B56D-5E8805F49F1DQ37970424-20C8E1F3-E54D-4E92-BF51-D782CCD054FFQ38002109-83B86651-4A9C-4992-A96F-FA949C4D4A83Q38010341-4164F205-4D1A-4F43-A586-837F0EC38155Q38014916-5762AB66-A22A-4D84-A290-5284C5695C52Q38066586-29A4BC79-BD2C-4C99-A63E-1EF3FEB74838Q38066877-E8FA8F6E-4AB8-4FDA-9B0E-FE0C0EB4A92CQ38067694-BF523076-F413-4786-AED7-1BF5A32E95ECQ38100859-C9CF64B3-459B-4938-9D31-BFFDFFD23A50Q38206823-DCAC04D7-0F4F-4B2E-9BAB-EA61F98097C9Q38227257-9AE23AC4-294B-4115-BEA1-7FF0386E4A83Q38247785-6319EE06-C65B-445A-A0F5-3008B6F13908
P2860
Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Maribavir prophylaxis for prev ...... -controlled, randomised trial.
@en
Maribavir prophylaxis for prev ...... -controlled, randomised trial.
@nl
type
label
Maribavir prophylaxis for prev ...... -controlled, randomised trial.
@en
Maribavir prophylaxis for prev ...... -controlled, randomised trial.
@nl
prefLabel
Maribavir prophylaxis for prev ...... -controlled, randomised trial.
@en
Maribavir prophylaxis for prev ...... -controlled, randomised trial.
@nl
P2093
P50
P921
P1476
Maribavir prophylaxis for prev ...... -controlled, randomised trial.
@en
P2093
Augustin Ferrant
Drew J Winston
Hongzi Chen
Jeffrey H Lipton
Johan Maertens
Lynne Strasfeld
Maribavir 1263-300 Clinical Study Group
Michael Schmitt
Roy F Chemaly
Stephen A Villano
P304
P356
10.1016/S1473-3099(11)70024-X
P50
P577
2011-03-21T00:00:00Z